Pulmonary fibrosis model of mice induced by different administration methods of bleomycin

[1]  Yanxia Rao,et al.  Microglia replacement by microglia transplantation (Mr MT) in the adult mouse brain , 2021, STAR protocols.

[2]  Kevin J. O'Brien,et al.  Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens , 2021, Frontiers in Medicine.

[3]  Xiufen Zheng,et al.  Anti-Fibrotic Effects of Low Toxic Microcystin-RR on Bleomycin-Induced Pulmonary Fibrosis: A Comparison with Microcystin-LR , 2021, Frontiers in Pharmacology.

[4]  Mark G. Jones,et al.  Repeat bronchoalveolar lavage in idiopathic pulmonary fibrosis: proceed with caution? , 2021, European Respiratory Journal.

[5]  A. Cochet,et al.  [18F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [18F]FDG PET/CT approach , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  V. Cottin,et al.  Spectrum of Fibrotic Lung Diseases. , 2020, The New England journal of medicine.

[7]  L. Richeldi,et al.  Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal? , 2020, European journal of internal medicine.

[8]  Feifei Nong,et al.  Prognostic significance of abnormal matrix collagen remodeling in colorectal cancer based on histologic and bioinformatics analysis , 2020, Oncology reports.

[9]  Q. Ding,et al.  A novel tree shrew model of pulmonary fibrosis , 2020, Laboratory Investigation.

[10]  R. Sistla,et al.  Biochanin-A ameliorates pulmonary fibrosis by suppressing the TGF-β mediated EMT, myofibroblasts differentiation and collagen deposition in in vitro and in vivo systems , 2020, Phytomedicine.

[11]  S. Walsh,et al.  Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis , 2020, Thorax.

[12]  Min Zhu,et al.  Exosomal miRNA Let-7 from Menstrual Blood-Derived Endometrial Stem Cells Alleviates Pulmonary Fibrosis through Regulating Mitochondrial DNA Damage , 2019, Oxidative medicine and cellular longevity.

[13]  Hyun J. Kim,et al.  Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry , 2019, Respiratory Research.

[14]  H. Goldberg.  Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials. , 2019, The New England journal of medicine.

[15]  Yu-Show Fu,et al.  Reversal of bleomycin-induced rat pulmonary fibrosis by a xenograft of human umbilical mesenchymal stem cells from Wharton's jelly , 2019, Theranostics.

[16]  C. Page,et al.  Use of animal models in IPF research. , 2018, Pulmonary pharmacology & therapeutics.

[17]  J. Li,et al.  Submicron emulsion of cinnamaldehyde ameliorates bleomycin-induced idiopathic pulmonary fibrosis via inhibition of inflammation, oxidative stress and epithelial-mesenchymal transition. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[18]  M. Molina-Molina,et al.  Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells , 2018, BMC Pulmonary Medicine.

[19]  Q. Lian,et al.  Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice , 2017, Scientific Reports.

[20]  R. Borie,et al.  [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis , 2017, Respiratory Research.

[21]  L. Richeldi,et al.  Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history , 2016, Respirology.

[22]  V. Della Latta,et al.  Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. , 2015, Pharmacological research.

[23]  L. Tao,et al.  [Murine pulmonary fibrosis model induced by repeated low-dose intravenous injection and intratracheal instillation of bleomycin]. , 2013, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[24]  Cuiping Mao,et al.  All-transretinoic acid ameliorates bleomycin-induced lung fibrosis by downregulating the TGF-β1/Smad3 signaling pathway in rats , 2013, Laboratory Investigation.

[25]  M. Mine,et al.  Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis , 2013, Cell Stress and Chaperones.

[26]  S. Toda,et al.  Periostin, a matricellular protein, plays a role in the induction of chemokines in pulmonary fibrosis. , 2012, American journal of respiratory cell and molecular biology.

[27]  W. Lawson,et al.  Progress Toward Improving Animal Models for Idiopathic Pulmonary Fibrosis , 2011, The American journal of the medical sciences.

[28]  L. Gleaves,et al.  Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[29]  N. Kohno,et al.  Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis , 2010, Thorax.

[30]  H. Oku,et al.  Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. , 2008, European journal of pharmacology.

[31]  S. Kleeberger,et al.  Mouse Models of Bleomycin‐Induced Pulmonary Fibrosis , 2008, Current protocols in pharmacology.

[32]  C. Lisboa,et al.  Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. , 2001, American journal of respiratory and critical care medicine.

[33]  J. Last,et al.  Type I collagen content is increased in lungs of patients with adult respiratory distress syndrome. , 1983, Thorax.

[34]  T. Takita,et al.  Chemistry of bleomycin. XXI. Metal-complex of bleomycin and its implication for the mechanism of bleomycin action. , 1978, The Journal of antibiotics.

[35]  I. Adamson,et al.  The pathogenesis of bleomycin-induced pulmonary fibrosis in mice. , 1974, The American journal of pathology.

[36]  N. Bleehen,et al.  Early Clinical Experience with Bleomycin in the United Kingdom in Series of 105 Patients , 1972, British medical journal.

[37]  Y. Yamaguchi,et al.  Cross-Talk between Transforming Growth Factor-b and Periostin Can Be Targeted for Pulmonary Fibrosis , 2020 .

[38]  S. Phan,et al.  The Bleomycin Model of Pulmonary Fibrosis. , 2017, Methods in molecular biology.

[39]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[40]  Dean P. Jones,et al.  Oxidation of extracellular cysteine/cystine redox state in bleomycin-induced lung fibrosis. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[42]  M. Luna,et al.  Bleomycin hypersensitivity pneumonitis. , 1978, Annals of internal medicine.